CD34 and basal cell carcinoma: This pathway is aberrantly activated in many solid tumors including basal cell carcinoma.51 This feature has been exploited for the development of Vismodegib, an antagonist of SMO.13 However, in contrast to several other cancers, SMO expression in AML cells is five times lower than in CD34+ cells in our study.